
BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging.
BioAge Labs revenue
BioAge Labs' annual revenue was $9M in December 2025 (Stock Analysis).
| As of | Revenue | Source |
|---|---|---|
| Dec 2025 | $9M | Stock Analysis |
BioAge Labs market cap
BioAge Labs is a public company. Its market capitalisation was $329.5M in September 2026.
BioAge Labs CEO
Kristen Fortney is CEO of BioAge Labs.
BioAge Labs FAQ
What is BioAge Labs' revenue?
BioAge Labs' annual revenue was $9M in December 2025, according to Stock Analysis.
Is BioAge Labs publicly traded?
Yes. BioAge Labs is a public company, with a market capitalisation of $329.5M in September 2026.
Who is the CEO of BioAge Labs?
Kristen Fortney is the CEO of BioAge Labs.
Categories
How this page is sourced
1 from public sources. Founder figures link to the second they were said; public figures name their source; estimates are marked EST and say whose they are. Not financial advice.
Updated Sep 28, 2026Data disclaimerReport a correctionClaim this profileRun BioAge Labs? Join the podcast